Email updates

Keep up to date with the latest news and content from European Journal of Medical Research and BioMed Central.

Open Access Case report

Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy

Pedro Cuevas1*, Luis A Outeiriño2, Carlos Azanza2, Javier Angulo1 and Guillermo Giménez-Gallego3

Author Affiliations

1 Departamento de Investigación, IRYCIS, Hospital Universitario Ramón y Cajal, Ctra. de Colmenar, km. 9.100, Madrid -28034, Spain

2 Departamento de Oftalmología, Hospital de Día Pío XII, Cuesta Sagrados Corazones 4, Madrid -28016, Spain

3 Departamento de Estructura y Función de Proteínas, Centro de Investigaciones Biológicas, CSIC. C/ Ramiro de Maeztu 9, Madrid -28040, Spain

For all author emails, please log on.

European Journal of Medical Research 2012, 17:22  doi:10.1186/2047-783X-17-22

Published: 12 July 2012

Abstract

Purpose

To report the anatomic and functional outcome of intravitreal dobesilate to treat recurrent central serous chorioretinopathy (CSC).

Methods

This is an interventional case report in which dobesilate was intravitreally injected in a case of recurrent CSC. Main measures included fundoscopy, Snellen visual acuity (VA) testing, fluorescein angiography and optical coherence tomography (OCT).

Results

We present anatomical and functional evidences, obtained as early as eleven days after the treatment, of the efficacy of intravitreal dobesilate, in the treatment of chronic CSC condition. The effect after intravitreal dobesilate injection for CSC might be related to the normalization of retinal architecture.

Conclusions

Intravitreal dobesilate may be an effective treatment option for recurrent CSC.

Keywords:
Central serous chorioretinopathy; Fibroblast growth factor; Dobesilate; Intravitreal injection